Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct;9(5):661-664.
doi: 10.21037/hbsn.2020.01.05.

FIB-4 score and hepatocellular carcinoma risk after hepatitis C virus cure: time to revise surveillance?

Antonio Saviano  1   2   3 , Simona Tripon  1   2 , Thomas F Baumert  1   2   3   4
Affiliations
Editorial

FIB-4 score and hepatocellular carcinoma risk after hepatitis C virus cure: time to revise surveillance?

Antonio Saviano et al. Hepatobiliary Surg Nutr. 2020 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/hbsn.2020.01.05). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
HCC risk after DAA treatment according to cirrhosis status and FIB-4. Cost-effectiveness is based on the traditional threshold of $50,000/quality-adjusted life year gained. HCC, hepatocellular carcinoma; HCV, hepatitis C virus; DAA, direct antiviral agent; SVR, sustained viral response. Data from Ioannou et al. (13).
See this image and copyright information in PMC

Comment on

References

    1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-73.e1. 10.1053/j.gastro.2011.12.061 - DOI - PMC - PubMed
    1. Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019;393:1453-64. 10.1016/S0140-6736(18)32111-1 - DOI - PubMed
    1. Kanwal F, Kramer J, Asch SM, et al. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology 2017;153:996-1005.e1. 10.1053/j.gastro.2017.06.012 - DOI - PubMed
    1. Hamdane N, Juhling F, Crouchet E, et al. HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response. Gastroenterology 2019;156:2313-29.e7. 10.1053/j.gastro.2019.02.038 - DOI - PMC - PubMed
    1. EASL Clinical Practice Guidelines : Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236. 10.1016/j.jhep.2018.03.019 - DOI - PubMed